We are international
Donate
TEXT SIZE   


ASH 2015: Dr. Paul Richardson's ASH Overview

Dr. Paul Richardson
Dana-Farber Cancer Institute
Boston, MA

12.10.15

 

With support from Amgen, Bristol Myers Squibb, Celgene, Janssen Pharmaceuticals, and Takeda Oncology.


 related articles
ASH 2015: Dr. Paul Richardson's ASH Overview
Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial)
The IMWG Conference Series "Making Sense of Treatment"
57th ASH Annual Meeting | Dec. 7, 2015
Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up
Oral Doxycycline Improves Outcomes of Stage III AL Amyloidosis - a Matched Case Control Study
ASH 2015: Dr. Saad Usmani ASH Overview
ASH 2015: Dr. Sagar Lonial ASH Overview
ASH 2015: Dr. Morie Gertz ASH Overview
ASH 2015: Dr. Kenneth Anderson ASH Overview
Global Advances in Myeloma:
Providing Best Options for Treatment in 2015


You might also be interested in:

ASH 2015: Dr. Paul Richardson's ASH Overview

Dr. Paul Richardson
Dana-Farber Cancer Institute
Boston, MA


Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial)

Dr. Michel Attal
Institut Universitaire du Cancer de Toulouse-Oncopole
Toulouse, France


The IMWG Conference Series "Making Sense of Treatment"
57th ASH Annual Meeting | Dec. 7, 2015

Drs. Brian GM Durie, Joseph Mikhael, Antonio Palumbo, and Paul Richardson discusses the latest news and trends in the treatment of Multiple Myeloma.

  • MRD Testing:  Is it Ready for Primetime?
  • Frontline Therapy:  What are the Best Option in 2015/2016
  • Relapse: How Do You Prioritize New Choices?
  • New Agents: Which Are Best and How Do We Assess? 

Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma

Dr. Saad Usmani
Levine Cancer Institute
Charlotte, NC


Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up

Dr. Meletios Dimopoulos
National and Kapodistrian University of Athens
School of Medicine
Athens, Greece


Oral Doxycycline Improves Outcomes of Stage III AL Amyloidosis - a Matched Case Control Study

Dr. Ashutosh Wechalekar
National Amyloidosis Centre
University College London
London, United Kingdom


ASH 2015: Dr. Saad Usmani ASH Overview

Dr. Saad Usmani
Levine Cancer Institute
Carolinas Healthcare System
Charlotte, NC


ASH 2015: Dr. Sagar Lonial ASH Overview

Dr. Sagar Lonial
Emory University
Atlanta, GA


ASH 2015: Dr. Morie Gertz ASH Overview

Dr. Morie Gertz
Mayo Clinic
Rochester, MN


ASH 2015: Dr. Kenneth Anderson ASH Overview

Dr. Kenneth Anderson
Dana-Farber Cancer Institute
Boston, MA


Global Advances in Myeloma:
Providing Best Options for Treatment in 2015

Join us for a provocative program format that includes “point and counterpoint” presentations and interactive case discussions to provide varied perspectives on new data, guideline changes, and expert recommendations in multiple myeloma.

Interact with international experts as they debate clinical questions and discuss how these challenges affect therapeutic decisions faced by clinicians treating myeloma. 

Friday Satellite Symposium preceding the 57th ASH Annual Meeting.